Active Substance: Deferasirox.
Overview
Welcome to Dwaey, specifically on JADENU 360mg page.
This medicine contains an important and useful components, as it consists of
Deferasiroxis available in the market in concentration
Deferasirox
Monitor renal function and CBC before starting treatment and regularly during treatment; may need to reduce dose or stop treatment if serum creatinine levels are persistently elevated. May increase LFTs. Perform audiological and ophthamological tests before starting treatment and yrly thereafter. Pregnancy. Lactation: not known whether excreted in breast milk, use caution
Chronic iron overload.
Hypersensitivity.
>10% Serum creatinine increase (dose related; 7-38%),Abdominal pain (21-28%),Nausea (11-23%),Vomiting (10-21%),Diarrhea (12-20%),Proteinuria (19%),Pyrexia (19%),Headache (16%),Cough (14%),Nasopharyngitis (13%),Pharyngolaryngeal pain (11%),Influenza (11%),Rash (8-11%) 1-10% Respiratory tract infection (10%),Bronchitis (9%),ALT increased (2-8%),Arthralgia, back pain (6-7%),Acute tonsillitis (6%),Rhinitis (6%),Fatigue (6%),Ear infection (5%),Transaminitis (4%),Urticaria (4%) <1% Anaphylaxis,Angioedema,Cytopenias, including agranulocytosis, neutropenia and thrombocytopenia; leukocytoclastic vasculitis Potentially Fatal: Acute renal failure, serious hypersensitivity reactions such as angioedema and anaphylaxis.
3
Deferasirox is an orally active chelator that is selective for iron (as Fe3+ ion). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. It is used in the management of chronic iron overload.
Not to be used with aluminium-containing antacids as it may chelate aluminium.
Information not available